Nonclinical regulatory immunotoxicity testing of nanomedicinal products: Proposed strategy and possible pitfalls

Christina Giannakou, Margriet V. D. Z. Park*, Irene E. M. Bosselaers, Wim H. de Jong, Jan Willem van der Laan, Henk van Loveren, Rob J. Vandebriel, Robert E. Geertsma

*Corresponding author for this work

Research output: Contribution to journal(Systematic) Review article peer-review

4 Citations (Web of Science)

Abstract

Various nanomedicinal products (NMPs) have been reported to induce an adverse immune response, which may be related to their tendency to accumulate in or target cells of the immune system. Therefore, before their market authorization, NMPs should be thoroughly evaluated for their immunotoxic potential. Nonclinical regulatory immunotoxicity testing of nonbiological medicinal products, including NMPs, is currently performed by following the guideline S8 "Immunotoxicity Studies for Human Pharmaceuticals" of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH). However, this guideline does not cover all the immunotoxicity endpoints reported for NMPs in the literature, such as complement activation related pseudo allergy, hypersensitivity and immunosuppression. In addition, ICH-S8 does not provide any nanospecific testing considerations, which is important given their tendency to interfere with many commonly used toxicity assays. We therefore propose a nonclinical regulatory immunotoxicity assessment strategy, which considers the immunotoxicity endpoints currently missing in the ICH-S8. We also list the known pitfalls related to the testing of NMPs and how to tackle them. Next to defining the relevant physicochemical and pharmacokinetic properties of the NMP and its intended use, the proposed strategy includes an in vitro assay battery addressing various relevant immunotoxicity endpoints. A weight of evidence evaluation of this information can be used to shape the type and design of further in vivo investigations. The final outcome of the immunotoxicity assessment can be included in the overall risk assessment of the NMP and provide alerts for relevant endpoints to address during clinical investigation.

This article is categorized under:

Toxicology and Regulatory Issues in Nanomedicine > Regulatory and Policy Issues in Nanomedicine

Toxicology and Regulatory Issues in Nanomedicine > Toxicology of Nanomaterials

Original languageEnglish
Article number1633
Number of pages16
JournalWiley Interdisciplinary Reviews-Nanomedicine and Nanobiotechnology
Volume12
Issue number5
DOIs
Publication statusPublished - Sep 2020

Keywords

  • ICH-S8
  • immunotoxicity
  • in vitro
  • nanomedicinal product
  • regulatory
  • COMPLEMENT ACTIVATION
  • SILVER NANOPARTICLES
  • TISSUE DISTRIBUTION
  • SKIN INTERACTIONS
  • IN-VITRO
  • TOXICITY
  • INFLAMMASOME
  • ACCUMULATION
  • DISEASE

Cite this